Atricure Inc. Stock
Atricure Inc. Stock
Atricure Inc. gained 1.810% today.
Atricure Inc. is currently one of the favorites of our community with 14 Buy predictions and no Sell predictions.
With a target price of 46 € there is a positive potential of 36.09% for Atricure Inc. compared to the current price of 33.8 €.
Pros and Cons of Atricure Inc. in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atricure Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atricure Inc. | 1.810% | 7.792% | 22.963% | -46.452% | -46.452% | -46.452% | -10.270% |
| SI-BONE Inc | -3.590% | 4.969% | 30.000% | 35.200% | 30.000% | - | - |
| Orasure Tech | -0.940% | 2.913% | 2.913% | -40.782% | -38.012% | -54.506% | -79.615% |
| Lantheus Holdings Inc | -1.140% | 5.187% | 21.159% | -36.459% | -38.615% | 4.980% | - |
Comments
AtriCure, Inc. (NASDAQ: ATRC) had its price target raised by analysts at Needham & Company LLC from $44.00 to $45.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure, Inc. (NASDAQ: ATRC) had its price target lowered by analysts at UBS Group AG from $60.00 to $58.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure, Inc. (NASDAQ: ATRC) had its price target lowered by analysts at Needham & Company LLC from $51.00 to $44.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
News
Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?
Sven Wehrwein, a member of the Board of Directors at AtriCure (NASDAQ:ATRC), exercised 10,000 non-qualified stock options and immediately sold the underlying shares in derivative transactions on
AtriCure (ATRC) Q2 Revenue Jumps 17%
AtriCure (NASDAQ:ATRC), a medical device company specializing in cardiac surgical technologies, delivered its earnings release on July 29, 2025, reporting results that outpaced Wall Street consensus